Revolution Medicines
Healthcare & Life Sci
Company overview
Revolution Medicines is a biopharmaceutical company. It develops targeted medicines for cancers driven by RAS gene mutations, known as RAS-addicted cancers. Its pipeline includes RAS(ON) inhibitor drugs called daraxonrasib, elironrasib and zoldonrasib, which are in clinical trials.
The FDA approved daraxonrasib in August 2026. It is the first RAS-targeted therapy approved for metastatic pancreatic cancer, marking a step from the pipeline to an approved medicine for patients. Revolution Medicines is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Redwood City, United States